A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
18 11 2019
Historique:
accepted: 24 09 2019
revised: 12 08 2019
received: 03 04 2019
pubmed: 6 10 2019
medline: 13 5 2020
entrez: 6 10 2019
Statut: ppublish

Résumé

While biallelic mutations in the PALB2 tumor suppressor cause Fanconi anemia subtype FA-N, monoallelic mutations predispose to breast and familial pancreatic cancer. Although hundreds of missense variants in PALB2 have been identified in patients to date, only a few have clear functional and clinical relevance. Herein, we investigate the effects of 44 PALB2 variants of uncertain significance found in breast cancer patients and provide detailed analysis by systematic functional assays. Our comprehensive functional analysis reveals two hotspots for potentially deleterious variations within PALB2, one at each terminus. PALB2 N-terminus variants p.P8L [c.23C>T], p.Y28C [c.83A>G], and p.R37H [c.110G>A] compromised PALB2-mediated homologous recombination. At the C-terminus, PALB2 variants p.L947F [c.2841G>T], p.L947S [c.2840T>C], and most strikingly p.T1030I [c.3089C>T] and p.W1140G [c.3418T>C], stood out with pronounced PARP inhibitor sensitivity and cytoplasmic accumulation in addition to marked defects in recruitment to DNA damage sites, interaction with BRCA2 and homologous recombination. Altogether, our findings show that a combination of functional assays is necessary to assess the impact of germline missense variants on PALB2 function, in order to guide proper classification of their deleteriousness.

Identifiants

pubmed: 31586400
pii: 5581727
doi: 10.1093/nar/gkz780
pmc: PMC6847799
doi:

Substances chimiques

Fanconi Anemia Complementation Group N Protein 0
PALB2 protein, human 0
Rad51 Recombinase EC 2.7.7.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10662-10677

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Trends Biochem Sci. 2019 Mar;44(3):226-240
pubmed: 30638972
Nucleic Acids Res. 2006 Mar 06;34(5):1317-25
pubmed: 16522644
Int J Mol Sci. 2017 Aug 31;18(9):null
pubmed: 28858227
BMC Genomics. 2013;14 Suppl 3:S3
pubmed: 23819870
Clin Cancer Res. 2015 Feb 15;21(4):819-32
pubmed: 25500058
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
Breast Cancer Res. 2016 Nov 9;18(1):111
pubmed: 27829436
Nat Genet. 2007 Feb;39(2):159-61
pubmed: 17200672
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6788-93
pubmed: 17420451
Nature. 2007 Mar 15;446(7133):316-9
pubmed: 17287723
Lancet Oncol. 2015 Aug;16(8):e375-6
pubmed: 26248842
Science. 2009 Apr 10;324(5924):217
pubmed: 19264984
Breast Cancer Res. 2017 Aug 15;19(1):93
pubmed: 28810913
J Biol Chem. 2009 Jul 3;284(27):18302-10
pubmed: 19423707
Nucleic Acids Res. 2015 Oct 30;43(19):9379-92
pubmed: 26429972
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Mol Cell Biol. 2012 Apr;32(8):1506-17
pubmed: 22331464
BMC Med Genet. 2010 Feb 02;11:20
pubmed: 20122277
Mol Cell. 2017 Jan 19;65(2):336-346
pubmed: 28089683
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7671-7676
pubmed: 28673974
N Engl J Med. 2014 Aug 7;371(6):497-506
pubmed: 25099575
Front Oncol. 2018 Oct 25;8:480
pubmed: 30410870
NPJ Genom Med. 2016;1:null
pubmed: 28781887
Gene. 1989 Apr 15;77(1):51-9
pubmed: 2744487
Nat Struct Mol Biol. 2010 Oct;17(10):1255-9
pubmed: 20871616
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60
pubmed: 19369211
Nucleic Acids Res. 2017 Mar 17;45(5):2644-2657
pubmed: 28158555
Oncogene. 2013 Jul 25;32(30):3552-8
pubmed: 22964643
Curr Biol. 2009 Mar 24;19(6):524-9
pubmed: 19268590
J Biol Chem. 2019 Apr 12;294(15):5980-5992
pubmed: 30765603
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1078-88
pubmed: 21447777
Nature. 2015 Feb 12;518(7538):258-62
pubmed: 25642963
Nat Genet. 2007 Feb;39(2):162-4
pubmed: 17200671
Mol Cancer Res. 2009 Jul;7(7):1110-8
pubmed: 19584259
Oncogene. 2017 Jul 20;36(29):4161-4170
pubmed: 28319063
Elife. 2017 Feb 27;6:
pubmed: 28240985
Nucleic Acids Res. 2012 Nov 1;40(20):10312-23
pubmed: 22941656
Nat Genet. 2007 Feb;39(2):165-7
pubmed: 17200668
Am J Hum Genet. 2016 Oct 6;99(4):877-885
pubmed: 27666373
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Nature. 2018 Oct;562(7726):217-222
pubmed: 30209399
EMBO Rep. 2009 Sep;10(9):990-6
pubmed: 19609323
EMBO Rep. 2012 Feb 01;13(2):135-41
pubmed: 22193777
Nature. 2015 Feb 12;518(7538):254-7
pubmed: 25642960
J Cell Sci. 2010 Apr 1;123(Pt 7):1124-30
pubmed: 20332121
Mol Cell. 2006 Jun 23;22(6):719-29
pubmed: 16793542
Nat Struct Mol Biol. 2010 Oct;17(10):1247-54
pubmed: 20871615
Cell Rep. 2014 Feb 13;6(3):553-64
pubmed: 24485656
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30377213
Nat Genet. 2018 Jun;50(6):874-882
pubmed: 29785012
Biochemistry. 2018 Nov 27;57(47):6581-6591
pubmed: 30289697
Nature. 2015 Dec 17;528(7582):422-6
pubmed: 26649820
Pediatr Blood Cancer. 2015 Jan;62(1):91-8
pubmed: 25263539
Biochem J. 2014 Jun 15;460(3):331-42
pubmed: 24870022
Nat Genet. 2016 Dec;48(12):1581-1586
pubmed: 27776117
J Biol Chem. 2009 Aug 7;284(32):21127-31
pubmed: 19553677
Oncogene. 2014 Oct 2;33(40):4803-12
pubmed: 24141787

Auteurs

Amélie Rodrigue (A)

CHU de Québec-Université Laval, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology; Laval University Cancer Research Center, Québec City, QC G1V 0A6, Canada.

Guillaume Margaillan (G)

CHU de Québec-Université Laval Research Center, Genomics Center, Québec City, QC, Canada.

Thiago Torres Gomes (T)

Instituto Nacional de Câncer, Centro de Pesquisa, Programa de Pesquisa Clínica, Rio de Janeiro, Brazil.
Instituto Federal do Rio de Janeiro, Laboratório de Genética Molecular, Maracanã, Rio de Janeiro, Brazil.

Yan Coulombe (Y)

CHU de Québec-Université Laval, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology; Laval University Cancer Research Center, Québec City, QC G1V 0A6, Canada.

Gemma Montalban (G)

CHU de Québec-Université Laval, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology; Laval University Cancer Research Center, Québec City, QC G1V 0A6, Canada.
CHU de Québec-Université Laval Research Center, Genomics Center, Québec City, QC, Canada.

Simone da Costa E Silva Carvalho (S)

CHU de Québec-Université Laval, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Instituto Nacional de Câncer, Centro de Pesquisa, Programa de Pesquisa Clínica, Rio de Janeiro, Brazil.
Department of Genetics at Ribeirão Preto Medical School, University of São Paulo; Center for Cell-Based Therapy (CEPID/FAPESP); National Institute of Science and Technology in Stem Cell and Cell Therapy (INCTC/CNPq), Ribeirão Preto, SP, Brazil.

Larissa Milano (L)

CHU de Québec-Université Laval, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology; Laval University Cancer Research Center, Québec City, QC G1V 0A6, Canada.

Mandy Ducy (M)

CHU de Québec-Université Laval, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology; Laval University Cancer Research Center, Québec City, QC G1V 0A6, Canada.
CHU de Québec-Université Laval Research Center, Genomics Center, Québec City, QC, Canada.

Giuliana De-Gregoriis (G)

Instituto Nacional de Câncer, Centro de Pesquisa, Programa de Pesquisa Clínica, Rio de Janeiro, Brazil.
Instituto Federal do Rio de Janeiro, Laboratório de Genética Molecular, Maracanã, Rio de Janeiro, Brazil.

Graham Dellaire (G)

Department of Pathology, Dalhousie University, Halifax, NS, Canada.

Wilson Araújo da Silva (W)

Department of Genetics at Ribeirão Preto Medical School, University of São Paulo; Center for Cell-Based Therapy (CEPID/FAPESP); National Institute of Science and Technology in Stem Cell and Cell Therapy (INCTC/CNPq), Ribeirão Preto, SP, Brazil.

Alvaro N Monteiro (AN)

H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Marcelo A Carvalho (MA)

Instituto Nacional de Câncer, Centro de Pesquisa, Programa de Pesquisa Clínica, Rio de Janeiro, Brazil.
Instituto Federal do Rio de Janeiro, Laboratório de Genética Molecular, Maracanã, Rio de Janeiro, Brazil.

Jacques Simard (J)

CHU de Québec-Université Laval Research Center, Genomics Center, Québec City, QC, Canada.

Jean-Yves Masson (JY)

CHU de Québec-Université Laval, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology; Laval University Cancer Research Center, Québec City, QC G1V 0A6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH